Congestion is an integral component of cardiorenal syndrome and portends an adverse impact on the outcomes.Recent studies suggest that congestion has the ability of modulating the interactions between the kidney and the heart in this setting.Peritoneal dialysis(PD) is a homebased therapeutic modality that is not only offered to patients with end-stage renal disease to provide solute clearance and ultrafiltration,but it has also been used in patients with refractory heart failure and fluid overload to help optimize volume status.Several uncontrolled studies and case series have so far evaluated the role of PD in management of hypervolemia for patients with heart failure.They have generally reported favorable results in this setting.However,the data on the outcomes of patients with end-stage renal disease and concomitant heart failure is mixed,and the proposed theoretical advantages of PD might not translate into improved clinical endpoints.Congestion is prevalent in this patient population and has a significant effect on their survival.As studies suggest that a significant subset of patients with end-stage renal disease who receive PD therapy are hypervolemic,suboptimal management of congestion could at least in part explain these conflicting results.PD is a highly flexible therapeutic modality and the choice of techniques,regimens,and solutions can affect its ability for optimization of fluid status.This article provides an overview of the currently available data on the role and clinical relevance of congestion in patients with cardiorenal syndrome and reviews potential options to enhance decongestion in these patients. Congestion is an integral component of cardiorenal syndrome and portends an adverse impact on the outcomes.Recent studies suggest that congestion has the ability of modulating the interactions between the kidney and the heart in this setting. Peritoneal dialysis (PD) is a homebased therapeutic modality that is not only offered to patients with end-stage renal disease to provide solute clearance and ultrafiltration, but it has also been used in patients with refractory heart failure and fluid overload to help optimize volume status. the role of PD in management of hypervolemia for patients with heart failure. They have generally reported favorable results in this setting. However, the data on the outcomes of patients with end-stage renal disease and concomitant heart failure is mixed, and the proposed theoretical advantages of PD might not translate into improved clinical endpoints.Congestion is prevalent in this patient populat Aspects suggest a significant subset of patients with end-stage renal disease who receive PD therapy are hypervolemic, suboptimal management of congestion could at least in part explain these conflicting results. PD is a highly flexible therapeutic modality and the choice of techniques, regimens, and solutions can affect its ability for optimization of fluid status. This article provides an overview of the currently available data on the role and clinical relevance of congestion in patients with cardiorenal syndrome and reviews potential options to enhance decongestion in these patients.